{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:11:22Z","timestamp":1794964282473,"version":"4.9.1"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI175439"],"award-info":[{"award-number":["R01 AI175439"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI136756"],"award-info":[{"award-number":["R01 AI136756"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI102766"],"award-info":[{"award-number":["R01 AI102766"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA134274"],"award-info":[{"award-number":["P30CA134274"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Flaviviruses are a family of related viruses that cause substantial global morbidity and mortality. Vaccination against one flavivirus can sometimes exacerbate disease caused by related viruses through antibody-dependent enhancement (ADE) or interfere with the efficacy of subsequent vaccines. To address this challenge, we develop a vaccine strategy by introducing G5C\/G102C mutations into the flavivirus envelope (E) glycoprotein. These mutations promote E dimerization through the formation of an inter-chain disulfide bond that conceals the immunodominant and ADE-prone fusion loop epitope (FLE). We validate this design on E proteins from multiple flaviviruses through biochemical, antigenic, and structural analyses. The resulting vaccine candidate, CC_FLE sE, derived from the Zika virus (ZIKV) and formulated with an advanced supramolecular adjuvant, provides significant protection in female mice challenged with ZIKV and prevents ADE caused by a related flavivirus, Dengue virus. In genetically modified mice expressing diverse human immunoglobulin loci, ZIKV CC_FLE sE induces robust neutralizing antibody responses targeting key ZIKV E protein epitopes, including the E-dimer\u2013dependent epitope (EDE), indicating that ZIKV CC_FLE sE can elicit protective antibody responses within the human na\u00efve B cell repertoire. Therefore, CC_FLE sE represents a promising strategy for developing flavivirus vaccines that minimize ADE risk while maintaining high protective efficacy.<\/jats:p>","DOI":"10.1038\/s41467-025-67447-4","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:47:33Z","timestamp":1766404053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rational design of flavivirus E protein vaccine optimizes immunogenicity and mitigates antibody dependent enhancement risk"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-1277","authenticated-orcid":false,"given":"Yimeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Galkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5795-5815","authenticated-orcid":false,"given":"Ting-Juan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shridhar","family":"Bale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5029-6198","authenticated-orcid":false,"given":"Chi-I","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes L.","family":"Chenine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Turonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Greenhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn","family":"Wear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swagata","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1103-9608","authenticated-orcid":false,"given":"Hanne","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9687-9341","authenticated-orcid":false,"given":"Yan-Jang S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L.","family":"Vanlandingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Higgs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena G.","family":"Lapidus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9766-9995","authenticated-orcid":false,"given":"Thomas","family":"Fuerst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8824-1110","authenticated-orcid":false,"given":"David J.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Iffland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore C.","family":"Pierson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6186-6156","authenticated-orcid":false,"given":"Alexander K.","family":"Andrianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-5376","authenticated-orcid":false,"given":"Edwin","family":"Pozharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-2960","authenticated-orcid":false,"given":"Yuxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"67447_CR1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","volume":"5","author":"TC Pierson","year":"2020","unstructured":"Pierson, T. C. & Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796\u2013812 (2020).","journal-title":"Nat. Microbiol."},{"key":"67447_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1146\/annurev-med-040717-051127","volume":"70","author":"MS Diamond","year":"2019","unstructured":"Diamond, M. S., Ledgerwood, J. E. & Pierson, T. C. Zika Virus vaccine development: progress in the face of new challenges. Annu. Rev. Med. 70, 121\u2013135 (2019).","journal-title":"Annu. Rev. Med."},{"key":"67447_CR3","doi-asserted-by":"publisher","first-page":"aaf8160","DOI":"10.1126\/science.aaf8160","volume":"353","author":"J Lessler","year":"2016","unstructured":"Lessler, J. et al. Assessing the global threat from Zika virus. Science 353, aaf8160 (2016).","journal-title":"Science"},{"key":"67447_CR4","doi-asserted-by":"publisher","unstructured":"Dutta, S. K. & Langenburg, T. A Perspective on current flavivirus vaccine development: a brief review. Viruses 15, https:\/\/doi.org\/10.3390\/v15040860 (2023).","DOI":"10.3390\/v15040860"},{"key":"67447_CR5","unstructured":"Lindenbach, B. D., Thiel, H. J. & Rice, C. M. in Fields Virology Vol. 1 (eds David Mahan Knipe & Peter M. Howley) Ch. 1101, 1101\u20131152 (Lippincott Williams & Wilkins, 2007)."},{"key":"67447_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ni.3849","volume":"18","author":"E Fernandez","year":"2017","unstructured":"Fernandez, E. et al. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat. Immunol. 18, 1261\u20131269 (2017).","journal-title":"Nat. Immunol."},{"key":"67447_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109\u2013113 (2015).","journal-title":"Nature"},{"key":"67447_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cell.2017.04.024","volume":"169","author":"DF Robbiani","year":"2017","unstructured":"Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika Virus in Brazil and Mexico. Cell 169, 597\u2013609.e511 (2017).","journal-title":"Cell"},{"key":"67447_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","volume":"166","author":"H Zhao","year":"2016","unstructured":"Zhao, H. et al. Structural basis of Zika virus-specific antibody protection. Cell 166, 1016\u20131027 (2016).","journal-title":"Cell"},{"key":"67447_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14722","volume":"8","author":"SS Hasan","year":"2017","unstructured":"Hasan, S. S. et al. A human antibody against Zika virus crosslinks the E protein to prevent infection. Nat. Commun. 8, 14722 (2017).","journal-title":"Nat. Commun."},{"key":"67447_CR11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nature20564","volume":"540","author":"G Sapparapu","year":"2016","unstructured":"Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443\u2013447 (2016).","journal-title":"Nature"},{"key":"67447_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41591-019-0746-2","volume":"26","author":"V Dussupt","year":"2020","unstructured":"Dussupt, V. et al. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor. Nat. Med. 26, 228\u2013235 (2020).","journal-title":"Nat. Med."},{"key":"67447_CR13","doi-asserted-by":"publisher","first-page":"369ra179","DOI":"10.1126\/scitranslmed.aai8336","volume":"8","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl. Med. 8, 369ra179 (2016).","journal-title":"Sci. Transl. Med."},{"key":"67447_CR14","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1016\/j.cell.2022.10.023","volume":"185","author":"T Singh","year":"2022","unstructured":"Singh, T. et al. A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. Cell 185, 4826\u20134840.e4817 (2022).","journal-title":"Cell"},{"key":"67447_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.aaf8505","volume":"353","author":"K Stettler","year":"2016","unstructured":"Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823\u2013826 (2016).","journal-title":"Science"},{"key":"67447_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.chom.2016.04.013","volume":"19","author":"L Dai","year":"2016","unstructured":"Dai, L. et al. Structures of the Zika virus envelope protein and its complex with a flavivirus broadly protective antibody. Cell Host Microbe 19, 696\u2013704 (2016).","journal-title":"Cell Host Microbe"},{"key":"67447_CR17","doi-asserted-by":"publisher","first-page":"7852","DOI":"10.1073\/pnas.1607931113","volume":"113","author":"L Priyamvada","year":"2016","unstructured":"Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl. Acad. Sci. USA 113, 7852\u20137857 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67447_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15252\/embr.201745302","volume":"19","author":"FA Rey","year":"2018","unstructured":"Rey, F. A., Stiasny, K., Vaney, M. C., Dellarole, M. & Heinz, F. X. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 19, 206\u2013224 (2018).","journal-title":"EMBO Rep."},{"key":"67447_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4049\/jimmunol.1801149","volume":"202","author":"A Zhang","year":"2019","unstructured":"Zhang, A., Stacey, H. D., Mullarkey, C. E. & Miller, M. S. Original antigenic sin: how first exposure shapes lifelong anti-influenza virus immune responses. J. Immunol. 202, 335\u2013340 (2019).","journal-title":"J. Immunol."},{"key":"67447_CR20","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.immuni.2023.04.012","volume":"56","author":"M Koutsakos","year":"2023","unstructured":"Koutsakos, M. & Ellebedy, A. H. Immunological imprinting: Understanding COVID-19. Immunity 56, 909\u2013913 (2023).","journal-title":"Immunity"},{"key":"67447_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/oxfordjournals.aje.a113932","volume":"120","author":"N Sangkawibha","year":"1984","unstructured":"Sangkawibha, N. et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand I. 1980 outbreak. Am. J. Epidemiol. 120, 653\u2013669 (1984).","journal-title":"Am. J. Epidemiol."},{"key":"67447_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(14)60572-9","volume":"385","author":"MG Guzman","year":"2015","unstructured":"Guzman, M. G. & Harris, E. Dengue. Lancet 385, 453\u2013465 (2015).","journal-title":"Lancet"},{"key":"67447_CR23","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"67447_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1056\/NEJMoa1800820","volume":"379","author":"S Sridhar","year":"2018","unstructured":"Sridhar, S. et al. Effect of Dengue serostatus on Dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327\u2013340 (2018).","journal-title":"N. Engl. J. Med."},{"key":"67447_CR25","doi-asserted-by":"publisher","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","volume":"10","author":"R Shukla","year":"2020","unstructured":"Shukla, R., Ramasamy, V., Shanmugam, R. K., Ahuja, R. & Khanna, N. Antibody-dependent enhancement: a challenge for developing a safe Dengue vaccine. Front. Cell Infect. Microbiol. 10, 572681 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"67447_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-10901-1","volume":"7","author":"J George","year":"2017","unstructured":"George, J. et al. Prior exposure to Zika virus significantly enhances peak Dengue-2 Viremia in Rhesus Macaques. Sci. Rep. 7, 10498 (2017).","journal-title":"Sci. Rep."},{"key":"67447_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.chom.2018.09.015","volume":"24","author":"AM Fowler","year":"2018","unstructured":"Fowler, A. M. et al. Maternally acquired Zika antibodies enhance Dengue disease severity in mice. Cell Host Microbe 24, 743\u2013750.e745 (2018).","journal-title":"Cell Host Microbe"},{"key":"67447_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/infdis\/jiy482","volume":"219","author":"S Watanabe","year":"2019","unstructured":"Watanabe, S., Tan, N. W. W., Chan, K. W. K. & Vasudevan, S. G. Dengue Virus and Zika Virus serological cross-reactivity and their impact on pathogenesis in mice. J. Infect. Dis. 219, 223\u2013233 (2019).","journal-title":"J. Infect. Dis."},{"key":"67447_CR29","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"67447_CR30","doi-asserted-by":"publisher","first-page":"e1004386","DOI":"10.1371\/journal.ppat.1004386","volume":"10","author":"R de Alwis","year":"2014","unstructured":"de Alwis, R. et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 10, e1004386 (2014).","journal-title":"PLoS Pathog."},{"key":"67447_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745\u2013748 (2010).","journal-title":"Science"},{"key":"67447_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45806-x","volume":"15","author":"A Santos-Peral","year":"2024","unstructured":"Santos-Peral, A. et al. Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection. Nat. Commun. 15, 1696 (2024).","journal-title":"Nat. Commun."},{"key":"67447_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0133-5","volume":"4","author":"V Bradt","year":"2019","unstructured":"Bradt, V. et al. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. NPJ Vaccines 4, 38 (2019).","journal-title":"NPJ Vaccines"},{"key":"67447_CR34","doi-asserted-by":"publisher","first-page":"104815","DOI":"10.1016\/j.ebiom.2023.104815","volume":"97","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine. eBioMedicine 97, 104815 (2023).","journal-title":"eBioMedicine"},{"key":"67447_CR35","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S1473-3099(23)00192-5","volume":"23","author":"MA Koren","year":"2023","unstructured":"Koren, M. A. et al. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial. Lancet Infect. Dis. 23, 1175\u20131185 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"67447_CR36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cell.2017.03.016","volume":"169","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika Virus infection. Cell 169, 176 (2017).","journal-title":"Cell"},{"key":"67447_CR37","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","volume":"20","author":"JL Slon-Campos","year":"2019","unstructured":"Slon-Campos, J. L. et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nat. Immunol. 20, 1291\u20131298 (2019).","journal-title":"Nat. Immunol."},{"key":"67447_CR38","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","volume":"536","author":"G Barba-Spaeth","year":"2016","unstructured":"Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48\u201353 (2016).","journal-title":"Nature"},{"key":"67447_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-virology-092917-043300","volume":"5","author":"KA Dowd","year":"2018","unstructured":"Dowd, K. A. & Pierson, T. C. The many faces of a dynamic virion: implications of viral breathing on flavivirus biology and immunogenicity. Annu. Rev. Virol. 5, 185\u2013207 (2018).","journal-title":"Annu. Rev. Virol."},{"key":"67447_CR40","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41590-021-00966-6","volume":"22","author":"L Dai","year":"2021","unstructured":"Dai, L. et al. Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch. Nat. Immunol. 22, 958\u2013968 (2021).","journal-title":"Nat. Immunol."},{"key":"67447_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15411","volume":"8","author":"A Rouvinski","year":"2017","unstructured":"Rouvinski, A. et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).","journal-title":"Nat. Commun."},{"key":"67447_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01097-5","volume":"7","author":"JL Slon Campos","year":"2017","unstructured":"Slon Campos, J. L. et al. Temperature-dependent folding allows stable dimerization of secretory and virus-associated E proteins of Dengue and Zika viruses in mammalian cells. Sci. Rep. 7, 966 (2017).","journal-title":"Sci. Rep."},{"key":"67447_CR43","doi-asserted-by":"publisher","first-page":"10638","DOI":"10.1074\/jbc.RA119.007443","volume":"294","author":"C Yang","year":"2019","unstructured":"Yang, C. et al. Characterization of two engineered dimeric Zika virus envelope proteins as immunogens for neutralizing antibody selection and vaccine design.  J. Biol. Chem. 294, 10638\u201310648 (2019).","journal-title":"J. Biol. Chem."},{"key":"67447_CR44","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","volume":"20","author":"M Kanekiyo","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"67447_CR45","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1080\/22221751.2021.1994354","volume":"10","author":"M Gu","year":"2021","unstructured":"Gu, M. et al. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization. Emerg. Microbes Infect. 10, 2016\u20132029 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"67447_CR46","doi-asserted-by":"publisher","unstructured":"Magnani, D. M. et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aan8184 (2017).","DOI":"10.1126\/scitranslmed.aan8184"},{"key":"67447_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31111-y","volume":"13","author":"MC Vaney","year":"2022","unstructured":"Vaney, M. C. et al. Evolution and activation mechanism of the flavivirus class II membrane-fusion machinery. Nat. Commun. 13, 3718 (2022).","journal-title":"Nat. Commun."},{"key":"67447_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00024-6","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Near-atomic structure of Japanese encephalitis virus reveals critical determinants of virulence and stability. Nat. Commun. 8, 14 (2017).","journal-title":"Nat. Commun."},{"key":"67447_CR49","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1128\/CVI.00736-14","volume":"22","author":"F Wegmann","year":"2015","unstructured":"Wegmann, F. et al. The carbomer-lecithin adjuvant adjuplex has potent immunoactivating properties and elicits protective adaptive immunity against influenza virus challenge in mice. Clin. Vaccin. Immunol. 22, 1004\u20131012 (2015).","journal-title":"Clin. Vaccin. Immunol."},{"key":"67447_CR50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7774\/cevr.2015.4.1.23","volume":"4","author":"BS Powell","year":"2015","unstructured":"Powell, B. S., Andrianov, A. K. & Fusco, P. C. Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes. Clin. Exp. Vaccin. Res. 4, 23\u201345 (2015).","journal-title":"Clin. Exp. Vaccin. Res."},{"key":"67447_CR51","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jconrel.2020.12.001","volume":"329","author":"AK Andrianov","year":"2021","unstructured":"Andrianov, A. K. & Langer, R. Polyphosphazene immunoadjuvants: Historical perspective and recent advances. J. Control Release 329, 299\u2013315 (2021).","journal-title":"J. Control Release"},{"key":"67447_CR52","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.vaccine.2006.10.011","volume":"25","author":"G Mutwiri","year":"2007","unstructured":"Mutwiri, G. et al. Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1\/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204\u20131213 (2007).","journal-title":"Vaccine"},{"key":"67447_CR53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1021\/bm050790a","volume":"7","author":"AK Andrianov","year":"2006","unstructured":"Andrianov, A. K., Marin, A. & Chen, J. Synthesis, properties, and biological activity of Poly[di(sodium carboxylatoethylphenoxy)phosphazene]. Biomacromolecules 7, 394\u2013399 (2006).","journal-title":"Biomacromolecules"},{"key":"67447_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1586\/erv.11.26","volume":"10","author":"MA Tomai","year":"2011","unstructured":"Tomai, M. A. & Vasilakos, J. P. TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev. Vaccines 10, 405\u2013407 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"67447_CR55","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1586\/14760584.2013.811208","volume":"12","author":"JP Vasilakos","year":"2013","unstructured":"Vasilakos, J. P. & Tomai, M. A. The use of toll-like receptor 7\/8 agonists as vaccine adjuvants. Expert Rev. Vaccines 12, 809\u2013819 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"67447_CR56","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1586\/14760584.6.5.835","volume":"6","author":"MA Tomai","year":"2007","unstructured":"Tomai, M. A. et al. Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev. Vaccines 6, 835\u2013847 (2007).","journal-title":"Expert Rev. Vaccines"},{"key":"67447_CR57","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1021\/acsabm.0c00189","volume":"3","author":"AK Andrianov","year":"2020","unstructured":"Andrianov, A. K. et al. Supramolecular assembly of Toll-like receptor 7\/8 agonist into multimeric water-soluble constructs enables superior immune stimulation in vitro and in vivo. ACS Appl. Bio Mater. 3, 3187\u20133195 (2020).","journal-title":"ACS Appl. Bio Mater."},{"key":"67447_CR58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"67447_CR59","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1080\/21645515.2016.1219004","volume":"12","author":"NN Zhang","year":"2016","unstructured":"Zhang, N. N. et al. Characterization of the contemporary Zika virus in immunocompetent mice. Hum. Vaccin Immunother. 12, 3107\u20133109 (2016).","journal-title":"Hum. Vaccin Immunother."},{"key":"67447_CR60","doi-asserted-by":"publisher","first-page":"e1006004","DOI":"10.1371\/journal.ppat.1006004","volume":"12","author":"M Manangeeswaran","year":"2016","unstructured":"Manangeeswaran, M., Ireland, D. D. & Verthelyi, D. Zika (PRVABC59) infection is associated with T cell infiltration and neurodegeneration in CNS of immunocompetent neonatal C57Bl\/6 Mice. PLoS Pathog. 12, e1006004 (2016).","journal-title":"PLoS Pathog."},{"key":"67447_CR61","doi-asserted-by":"publisher","unstructured":"To, A. et al. Recombinant Zika virus subunits are immunogenic and efficacious in mice. mSphere 3, https:\/\/doi.org\/10.1128\/mSphere.00576-17 (2018).","DOI":"10.1128\/mSphere.00576-17"},{"key":"67447_CR62","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nature18952","volume":"536","author":"RA Larocca","year":"2016","unstructured":"Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature 536, 474\u2013478 (2016).","journal-title":"Nature"},{"key":"67447_CR63","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nature21428","volume":"543","author":"N Pardi","year":"2017","unstructured":"Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248\u2013251 (2017).","journal-title":"Nature"},{"key":"67447_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00426-0","volume":"7","author":"IJ Kim","year":"2022","unstructured":"Kim, I. J. et al. Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets. NPJ Vaccines 7, 9 (2022).","journal-title":"NPJ Vaccines"},{"key":"67447_CR65","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.cell.2017.04.038","volume":"169","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Immunization-elicited broadly protective antibody reveals Ebolavirus fusion loop as a site of vulnerability. Cell 169, 891\u2013904.e815 (2017).","journal-title":"Cell"},{"key":"67447_CR66","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.4049\/jimmunol.1502543","volume":"196","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. High-resolution longitudinal study of HIV-1 Env vaccine-elicited B cell responses to the virus primary receptor binding site reveals affinity maturation and clonal persistence. J. Immunol. 196, 3729\u20133743 (2016).","journal-title":"J. Immunol."},{"key":"67447_CR67","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.4049\/jimmunol.1901051","volume":"204","author":"A Galkin","year":"2020","unstructured":"Galkin, A. et al. HIV-1 gp120-CD4-induced antibody complex elicits CD4 binding site-specific antibody response in mice. J. Immunol. 204, 1543\u20131561 (2020).","journal-title":"J. Immunol."},{"key":"67447_CR68","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"67447_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25087-4","volume":"12","author":"A Antanasijevic","year":"2021","unstructured":"Antanasijevic, A. et al. Polyclonal antibody responses to HIV Env immunogens resolved using cryoEM. Nat. Commun. 12, 4817 (2021).","journal-title":"Nat. Commun."},{"key":"67447_CR70","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.immuni.2018.07.009","volume":"49","author":"M Bianchi","year":"2018","unstructured":"Bianchi, M. et al. Electron-microscopy-based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity 49, 288\u2013300.e288 (2018).","journal-title":"Immunity"},{"key":"67447_CR71","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","volume":"16","author":"W Dejnirattisai","year":"2015","unstructured":"Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170\u2013177 (2015).","journal-title":"Nat. Immunol."},{"key":"67447_CR72","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/0092-8674(91)90289-B","volume":"67","author":"C Berek","year":"1991","unstructured":"Berek, C., Berger, A. & Apel, M. Maturation of the immune response in germinal centers. Cell 67, 1121\u20131129 (1991).","journal-title":"Cell"},{"key":"67447_CR73","doi-asserted-by":"publisher","unstructured":"Burton, D. R. What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb. Perspect. Biol. 9, https:\/\/doi.org\/10.1101\/cshperspect.a030262 (2017).","DOI":"10.1101\/cshperspect.a030262"},{"key":"67447_CR74","doi-asserted-by":"publisher","first-page":"e0003903","DOI":"10.1371\/journal.pntd.0003903","volume":"9","author":"CT Tang","year":"2015","unstructured":"Tang, C. T. et al. An epitope-substituted DNA vaccine improves safety and immunogenicity against dengue virus type 2. PLoS Negl. Trop. Dis. 9, e0003903 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"67447_CR75","doi-asserted-by":"publisher","first-page":"102079","DOI":"10.1016\/j.jbc.2022.102079","volume":"298","author":"TTN Phan","year":"2022","unstructured":"Phan, T. T. N. et al. A conserved set of mutations for stabilizing soluble envelope protein dimers from dengue and Zika viruses to advance the development of subunit vaccines. J. Biol. Chem. 298, 102079 (2022).","journal-title":"J. Biol. Chem."},{"key":"67447_CR76","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","volume":"19","author":"JL Slon Campos","year":"2018","unstructured":"Slon Campos, J. L., Mongkolsapaya, J. & Screaton, G. R. The immune response against flaviviruses. Nat. Immunol. 19, 1189\u20131198 (2018).","journal-title":"Nat. Immunol."},{"key":"67447_CR77","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41579-018-0039-7","volume":"16","author":"P Abbink","year":"2018","unstructured":"Abbink, P., Stephenson, K. E. & Barouch, D. H. Zika virus vaccines. Nat. Rev. Microbiol 16, 594\u2013600 (2018).","journal-title":"Nat. Rev. Microbiol"},{"key":"67447_CR78","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."},{"key":"67447_CR79","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"67447_CR80","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"67447_CR81","doi-asserted-by":"publisher","first-page":"W474","DOI":"10.1093\/nar\/gkac307","volume":"50","author":"AE Badaczewska-Dawid","year":"2022","unstructured":"Badaczewska-Dawid, A. E., Nithin, C., Wroblewski, K., Kurcinski, M. & Kmiecik, S. MAPIYA contact map server for identification and visualization of molecular interactions in proteins and biological complexes. Nucleic Acids Res. 50, W474\u2013W482 (2022).","journal-title":"Nucleic Acids Res."},{"key":"67447_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-346","volume":"14","author":"DB Craig","year":"2013","unstructured":"Craig, D. B. & Dombkowski, A. A. Disulfide by design 2.0: a web-based tool for disulfide engineering in proteins. BMC Bioinform. 14, 346 (2013).","journal-title":"BMC Bioinform."},{"key":"67447_CR83","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1128\/JVI.06072-11","volume":"86","author":"VC Luca","year":"2012","unstructured":"Luca, V. C., AbiMansour, J., Nelson, C. A. & Fremont, D. H. Crystal structure of the Japanese encephalitis virus envelope protein. J. Virol. 86, 2337\u20132346 (2012).","journal-title":"J. Virol."},{"key":"67447_CR84","doi-asserted-by":"publisher","first-page":"18950","DOI":"10.1073\/pnas.1011036107","volume":"107","author":"B Kaufmann","year":"2010","unstructured":"Kaufmann, B. et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc. Natl. Acad. Sci. USA 107, 18950\u201318955 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67447_CR85","doi-asserted-by":"publisher","first-page":"e01907","DOI":"10.1128\/JVI.01907-20","volume":"95","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Prominent neutralizing antibody response targeting the Ebolavirus glycoprotein subunit interface elicited by immunization. J. Virol. 95, e01907\u2013e01920 (2021).","journal-title":"J. Virol."},{"key":"67447_CR86","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112\u2013124 (2008).","journal-title":"J. Immunol. Methods"},{"key":"67447_CR87","doi-asserted-by":"publisher","first-page":"e00910","DOI":"10.1128\/JVI.00910-17","volume":"91","author":"Y Wang","year":"2017","unstructured":"Wang, Y. et al. HIV-1 cross-reactive primary virus neutralizing antibody response elicited by immunization in nonhuman primates. J. Virol. 91, e00910\u2013e00917 (2017).","journal-title":"J. Virol."},{"key":"67447_CR88","doi-asserted-by":"publisher","first-page":"e1477","DOI":"10.1371\/journal.pntd.0001477","volume":"6","author":"AD Haddow","year":"2012","unstructured":"Haddow, A. D. et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. PLoS Negl. Trop. Dis. 6, e1477 (2012).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"67447_CR89","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1126\/science.aai9137","volume":"354","author":"KA Dowd","year":"2016","unstructured":"Dowd, K. A. et al. Rapid development of a DNA vaccine for Zika virus. Science 354, 237\u2013240 (2016).","journal-title":"Science"},{"key":"67447_CR90","doi-asserted-by":"publisher","first-page":"10208","DOI":"10.1128\/JVI.00062-06","volume":"80","author":"S Shresta","year":"2006","unstructured":"Shresta, S., Sharar, K. L., Prigozhin, D. M., Beatty, P. R. & Harris, E. Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80, 10208\u201310217 (2006).","journal-title":"J. Virol."},{"key":"67447_CR91","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114\u20131125.e1110 (2017).","journal-title":"Cell"},{"key":"67447_CR92","doi-asserted-by":"publisher","first-page":"12149","DOI":"10.1128\/JVI.01732-06","volume":"80","author":"T Oliphant","year":"2006","unstructured":"Oliphant, T. et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J. Virol. 80, 12149\u201312159 (2006).","journal-title":"J. Virol."},{"key":"67447_CR93","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.3389\/fimmu.2018.02464","volume":"9","author":"LO Medina","year":"2018","unstructured":"Medina, L. O. et al. A recombinant subunit based Zika virus vaccine is efficacious in non-human primates. Front. Immunol. 9, 2464 (2018).","journal-title":"Front. Immunol."},{"key":"67447_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-016-0322-5","volume":"17","author":"LH Ouisse","year":"2017","unstructured":"Ouisse, L. H. et al. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. BMC Biotechnol. 17, 3 (2017).","journal-title":"BMC Biotechnol."},{"key":"67447_CR95","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.4049\/jimmunol.1203041","volume":"190","author":"MJ Osborn","year":"2013","unstructured":"Osborn, M. J. et al. High-affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH\/Igkappa\/Iglambda loci bearing the rat CH region. J. Immunol. 190, 1481\u20131490 (2013).","journal-title":"J. Immunol."},{"key":"67447_CR96","doi-asserted-by":"publisher","first-page":"E738","DOI":"10.1073\/pnas.1319512111","volume":"111","author":"K Tran","year":"2014","unstructured":"Tran, K. et al. Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesign. Proc. Natl. Acad. Sci. USA 111, E738\u2013E747 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"67447_CR97","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jsb.2005.07.007","volume":"152","author":"DN Mastronarde","year":"2005","unstructured":"Mastronarde, D. N. Automated electron microscope tomography using robust prediction of specimen movements. J. Struct. Biol. 152, 36\u201351 (2005).","journal-title":"J. Struct. Biol."},{"key":"67447_CR98","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"67447_CR99","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"67447_CR100","doi-asserted-by":"publisher","unstructured":"Wang, R. Y. et al. Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. eLife 5, https:\/\/doi.org\/10.7554\/eLife.17219 (2016).","DOI":"10.7554\/eLife.17219"},{"key":"67447_CR101","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"PV Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D Struct. Biol. 74, 531\u2013544 (2018).","journal-title":"Acta Crystallogr. D Struct. Biol."},{"key":"67447_CR102","doi-asserted-by":"publisher","first-page":"W474","DOI":"10.1093\/nar\/gkw361","volume":"44","author":"J Dunbar","year":"2016","unstructured":"Dunbar, J. et al. SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 44, W474\u2013W478 (2016).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67447-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67447-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T21:03:00Z","timestamp":1767042180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67447-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["67447"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67447-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.L., Y.W., A.G., and A.K.A. are co-inventers of patent application titled \u201cEngineered Flavivirus Envelope Glycoprotein Immunogenic Compositions and Methods of Use\u201d (PCT\/US2023\/076441). Y.L. and X.S. are co-inventers of patent application titled \u201cAntibodies for Zika Virus\u201d (PCT\/US2023\/083586). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11558"}}